nodes	percent_of_prediction	percent_of_DWPC	metapath
Tafluprost—PTGFR—corpus luteum—polycystic ovary syndrome	0.197	0.398	CbGeAlD
Tafluprost—PTGFR—ovarian follicle—polycystic ovary syndrome	0.154	0.312	CbGeAlD
Tafluprost—PTGS2—ovarian follicle—polycystic ovary syndrome	0.0424	0.0856	CbGeAlD
Tafluprost—Bimatoprost—PTGER3—polycystic ovary syndrome	0.0141	0.386	CrCbGaD
Tafluprost—PTGFR—uterus—polycystic ovary syndrome	0.0141	0.0284	CbGeAlD
Tafluprost—PTGFR—adipose tissue—polycystic ovary syndrome	0.0138	0.0278	CbGeAlD
Tafluprost—PTGFR—adrenal gland—polycystic ovary syndrome	0.0123	0.0249	CbGeAlD
Tafluprost—PTGFR—female gonad—polycystic ovary syndrome	0.0115	0.0232	CbGeAlD
Tafluprost—PTGFR—endocrine gland—polycystic ovary syndrome	0.0107	0.0216	CbGeAlD
Tafluprost—Dinoprost Tromethamine—PTGER3—polycystic ovary syndrome	0.00854	0.234	CrCbGaD
Tafluprost—Iloprost—PLAT—polycystic ovary syndrome	0.00793	0.217	CrCbGaD
Tafluprost—Bimatoprost—AKR1C3—polycystic ovary syndrome	0.00592	0.162	CrCbGaD
Tafluprost—PTGS2—embryo—polycystic ovary syndrome	0.00573	0.0116	CbGeAlD
Tafluprost—PTGS2—adrenal cortex—polycystic ovary syndrome	0.0047	0.00949	CbGeAlD
Tafluprost—PTGS2—endometrium—polycystic ovary syndrome	0.0042	0.00847	CbGeAlD
Tafluprost—PTGS2—uterus—polycystic ovary syndrome	0.00387	0.00781	CbGeAlD
Tafluprost—PTGS2—pituitary gland—polycystic ovary syndrome	0.0038	0.00767	CbGeAlD
Tafluprost—PTGS2—adipose tissue—polycystic ovary syndrome	0.00378	0.00764	CbGeAlD
Tafluprost—PTGS2—adrenal gland—polycystic ovary syndrome	0.00339	0.00685	CbGeAlD
Tafluprost—PTGS2—female gonad—polycystic ovary syndrome	0.00316	0.00639	CbGeAlD
Tafluprost—PTGS2—vagina—polycystic ovary syndrome	0.00314	0.00635	CbGeAlD
Tafluprost—PTGFR—GPCRs, Class A Rhodopsin-like—PTAFR—polycystic ovary syndrome	0.00302	0.00645	CbGpPWpGaD
Tafluprost—PTGS2—endocrine gland—polycystic ovary syndrome	0.00294	0.00594	CbGeAlD
Tafluprost—PTGS2—C-MYB transcription factor network—PTCRA—polycystic ovary syndrome	0.00294	0.00628	CbGpPWpGaD
Tafluprost—PTGFR—GPCRs, Class A Rhodopsin-like—ADRA1D—polycystic ovary syndrome	0.00294	0.00627	CbGpPWpGaD
Tafluprost—PTGS2—Prostaglandin Synthesis and Regulation—CYP11A1—polycystic ovary syndrome	0.0029	0.00619	CbGpPWpGaD
Tafluprost—PTGFR—GPCRs, Class A Rhodopsin-like—ADRA1B—polycystic ovary syndrome	0.00286	0.00609	CbGpPWpGaD
Tafluprost—PTGFR—G alpha (q) signalling events—ADRA1A—polycystic ovary syndrome	0.0028	0.00598	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—PTGER3—polycystic ovary syndrome	0.00277	0.00591	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—LHCGR—polycystic ovary syndrome	0.00277	0.00591	CbGpPWpGaD
Tafluprost—PTGFR—G alpha (q) signalling events—GNRH1—polycystic ovary syndrome	0.0026	0.00556	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—PTAFR—polycystic ovary syndrome	0.00259	0.00553	CbGpPWpGaD
Tafluprost—PTGFR—GPCRs, Other—ADRB2—polycystic ovary syndrome	0.00259	0.00553	CbGpPWpGaD
Tafluprost—PTGS2—Overview of nanoparticle effects—BAX—polycystic ovary syndrome	0.00255	0.00544	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—NPB—polycystic ovary syndrome	0.00253	0.00539	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—ADRA1D—polycystic ovary syndrome	0.00251	0.00537	CbGpPWpGaD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—ADRA1A—polycystic ovary syndrome	0.0025	0.00534	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—ADRA1B—polycystic ovary syndrome	0.00245	0.00522	CbGpPWpGaD
Tafluprost—PTGFR—GPCRs, Class A Rhodopsin-like—FSHR—polycystic ovary syndrome	0.00237	0.00505	CbGpPWpGaD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—GNRH1—polycystic ovary syndrome	0.00233	0.00497	CbGpPWpGaD
Tafluprost—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FOXP3—polycystic ovary syndrome	0.00225	0.00481	CbGpPWpGaD
Tafluprost—PTGS2—Overview of nanoparticle effects—CRP—polycystic ovary syndrome	0.0022	0.00469	CbGpPWpGaD
Tafluprost—PTGFR—GPCRs, Class A Rhodopsin-like—ADRA1A—polycystic ovary syndrome	0.00216	0.00462	CbGpPWpGaD
Tafluprost—PTGS2—Prostaglandin Synthesis and Regulation—PRL—polycystic ovary syndrome	0.00216	0.00462	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—LHCGR—polycystic ovary syndrome	0.00211	0.0045	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—PTGER3—polycystic ovary syndrome	0.00211	0.0045	CbGpPWpGaD
Tafluprost—PTGS2—Signaling mediated by p38-alpha and p38-beta—ATF1—polycystic ovary syndrome	0.00209	0.00446	CbGpPWpGaD
Tafluprost—PTGFR—GPCRs, Class A Rhodopsin-like—ADRB3—polycystic ovary syndrome	0.00208	0.00445	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—FSHR—polycystic ovary syndrome	0.00203	0.00433	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—PTAFR—polycystic ovary syndrome	0.00197	0.00421	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—ADRA1D—polycystic ovary syndrome	0.00192	0.00409	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—ADRA1B—polycystic ovary syndrome	0.00186	0.00398	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—ADRA1A—polycystic ovary syndrome	0.00185	0.00396	CbGpPWpGaD
Tafluprost—PTGFR—GPCRs, Class A Rhodopsin-like—MTNR1B—polycystic ovary syndrome	0.00184	0.00393	CbGpPWpGaD
Tafluprost—PTGS2—Arachidonic acid metabolism—AKR1C3—polycystic ovary syndrome	0.00182	0.00388	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—ADRB3—polycystic ovary syndrome	0.00178	0.00381	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—LHB—polycystic ovary syndrome	0.00176	0.00376	CbGpPWpGaD
Tafluprost—PTGFR—G alpha (q) signalling events—GHRL—polycystic ovary syndrome	0.00176	0.00375	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—GNRH1—polycystic ovary syndrome	0.00172	0.00368	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—MTNR1B—polycystic ovary syndrome	0.00158	0.00336	CbGpPWpGaD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—GHRL—polycystic ovary syndrome	0.00157	0.00336	CbGpPWpGaD
Tafluprost—PTGS2—Overview of nanoparticle effects—BCL2—polycystic ovary syndrome	0.00155	0.00331	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—FSHR—polycystic ovary syndrome	0.00154	0.00329	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—NPB—polycystic ovary syndrome	0.00143	0.00305	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—ADRA1A—polycystic ovary syndrome	0.00141	0.00301	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—ADRB3—polycystic ovary syndrome	0.00136	0.0029	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—LHB—polycystic ovary syndrome	0.00134	0.00287	CbGpPWpGaD
Tafluprost—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—polycystic ovary syndrome	0.00133	0.00284	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—GNRH1—polycystic ovary syndrome	0.00131	0.0028	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—NPB—polycystic ovary syndrome	0.0013	0.00277	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—PLEKHG5—polycystic ovary syndrome	0.00129	0.00276	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—ARHGAP23—polycystic ovary syndrome	0.00126	0.0027	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—ARHGAP30—polycystic ovary syndrome	0.00126	0.0027	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—SCT—polycystic ovary syndrome	0.00126	0.00269	CbGpPWpGaD
Tafluprost—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—NAMPT—polycystic ovary syndrome	0.00125	0.00267	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—CYP1A1—polycystic ovary syndrome	0.00122	0.00261	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—INSR—polycystic ovary syndrome	0.00122	0.0026	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—MTNR1B—polycystic ovary syndrome	0.0012	0.00256	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—LHCGR—polycystic ovary syndrome	0.00119	0.00254	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—PTGER3—polycystic ovary syndrome	0.00119	0.00254	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—PLEKHG5—polycystic ovary syndrome	0.00117	0.0025	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—GHRL—polycystic ovary syndrome	0.00116	0.00249	CbGpPWpGaD
Tafluprost—PTGS2—S1P1 pathway—VEGFA—polycystic ovary syndrome	0.00116	0.00248	CbGpPWpGaD
Tafluprost—PTGS2—Arachidonic acid metabolism—CYP1A1—polycystic ovary syndrome	0.00114	0.00244	CbGpPWpGaD
Tafluprost—PTGFR—GPCRs, Class A Rhodopsin-like—ADRB2—polycystic ovary syndrome	0.00112	0.0024	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—PTAFR—polycystic ovary syndrome	0.00111	0.00238	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—PTGER3—polycystic ovary syndrome	0.00108	0.00231	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—LHCGR—polycystic ovary syndrome	0.00108	0.00231	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—ADRA1D—polycystic ovary syndrome	0.00108	0.00231	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—CCNB1—polycystic ovary syndrome	0.00105	0.00225	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—ADRA1B—polycystic ovary syndrome	0.00105	0.00225	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—PLAT—polycystic ovary syndrome	0.00105	0.00224	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—PTAFR—polycystic ovary syndrome	0.00101	0.00216	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—ADRA1D—polycystic ovary syndrome	0.000983	0.0021	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—ADRB2—polycystic ovary syndrome	0.000964	0.00206	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—TAB1—polycystic ovary syndrome	0.000958	0.00204	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—PDE3B—polycystic ovary syndrome	0.000958	0.00204	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—ADRA1B—polycystic ovary syndrome	0.000956	0.00204	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—GHRL—polycystic ovary syndrome	0.000887	0.00189	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—FLT4—polycystic ovary syndrome	0.000876	0.00187	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—FST—polycystic ovary syndrome	0.000875	0.00187	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—FSHR—polycystic ovary syndrome	0.000872	0.00186	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—PDE3B—polycystic ovary syndrome	0.00087	0.00186	CbGpPWpGaD
Tafluprost—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—polycystic ovary syndrome	0.000864	0.00184	CbGpPWpGaD
Tafluprost—PTGS2—Overview of nanoparticle effects—IL6—polycystic ovary syndrome	0.000803	0.00171	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—ADRA1A—polycystic ovary syndrome	0.000798	0.0017	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—NCOR1—polycystic ovary syndrome	0.000796	0.0017	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—FSHR—polycystic ovary syndrome	0.000792	0.00169	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—ADRB3—polycystic ovary syndrome	0.000768	0.00164	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—LPCAT2—polycystic ovary syndrome	0.000768	0.00164	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—NPB—polycystic ovary syndrome	0.000766	0.00164	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—LHB—polycystic ovary syndrome	0.000759	0.00162	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—GNRH1—polycystic ovary syndrome	0.000742	0.00158	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—ADRB2—polycystic ovary syndrome	0.000734	0.00157	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—NGFR—polycystic ovary syndrome	0.00073	0.00156	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—ADRA1A—polycystic ovary syndrome	0.000725	0.00155	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—SCT—polycystic ovary syndrome	0.000711	0.00152	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—ADRB3—polycystic ovary syndrome	0.000697	0.00149	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	0.000693	0.00148	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—LHB—polycystic ovary syndrome	0.000689	0.00147	CbGpPWpGaD
Tafluprost—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—polycystic ovary syndrome	0.000684	0.00146	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—GNAS—polycystic ovary syndrome	0.00068	0.00145	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	0.000678	0.00145	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—MTHFR—polycystic ovary syndrome	0.000677	0.00145	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—GNRH1—polycystic ovary syndrome	0.000674	0.00144	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—SCT—polycystic ovary syndrome	0.000646	0.00138	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—CRP—polycystic ovary syndrome	0.000645	0.00138	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PTGER3—polycystic ovary syndrome	0.000639	0.00136	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—LHCGR—polycystic ovary syndrome	0.000639	0.00136	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	0.000616	0.00131	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—TEAD2—polycystic ovary syndrome	0.000607	0.0013	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—AKR1C2—polycystic ovary syndrome	0.000607	0.0013	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—TOP2A—polycystic ovary syndrome	0.000607	0.00129	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	0.000602	0.00128	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PTAFR—polycystic ovary syndrome	0.000598	0.00128	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—ADRA1D—polycystic ovary syndrome	0.000581	0.00124	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—polycystic ovary syndrome	0.000572	0.00122	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—ADRA1B—polycystic ovary syndrome	0.000565	0.00121	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—INHBB—polycystic ovary syndrome	0.00055	0.00117	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—INS—polycystic ovary syndrome	0.000539	0.00115	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PDE3B—polycystic ovary syndrome	0.000514	0.0011	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—PNPLA2—polycystic ovary syndrome	0.000509	0.00109	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—GHRL—polycystic ovary syndrome	0.000501	0.00107	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—LEP—polycystic ovary syndrome	0.000499	0.00106	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—SERPINE1—polycystic ovary syndrome	0.000495	0.00106	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—SRD5A1—polycystic ovary syndrome	0.000482	0.00103	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—BCL2—polycystic ovary syndrome	0.000472	0.00101	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—AR—polycystic ovary syndrome	0.000472	0.00101	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—FSHR—polycystic ovary syndrome	0.000468	0.000999	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—STAR—polycystic ovary syndrome	0.00046	0.000982	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—POMC—polycystic ovary syndrome	0.000458	0.000978	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—GHRL—polycystic ovary syndrome	0.000455	0.000971	CbGpPWpGaD
Tafluprost—PTGS2—Disease—NMNAT3—polycystic ovary syndrome	0.000447	0.000953	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—RACGAP1—polycystic ovary syndrome	0.00044	0.000939	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—ADRA1A—polycystic ovary syndrome	0.000428	0.000914	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—FST—polycystic ovary syndrome	0.000417	0.00089	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	0.000415	0.000885	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.000412	0.000879	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—LHB—polycystic ovary syndrome	0.000407	0.000869	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—BAX—polycystic ovary syndrome	0.000402	0.000858	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.000398	0.000849	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—HSD3B1—polycystic ovary syndrome	0.000391	0.000835	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.000385	0.000823	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—GNAS—polycystic ovary syndrome	0.000385	0.000821	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—SCT—polycystic ovary syndrome	0.000381	0.000814	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—ADRB2—polycystic ovary syndrome	0.000377	0.000804	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—NMNAT3—polycystic ovary syndrome	0.000374	0.000798	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.000364	0.000777	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—FGF18—polycystic ovary syndrome	0.000358	0.000763	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—LHB—polycystic ovary syndrome	0.000357	0.000761	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—RBP4—polycystic ovary syndrome	0.000355	0.000757	CbGpPWpGaD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—polycystic ovary syndrome	0.000353	0.000754	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—GNAS—polycystic ovary syndrome	0.000349	0.000745	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—HSD3B2—polycystic ovary syndrome	0.000349	0.000744	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—LPCAT2—polycystic ovary syndrome	0.000342	0.00073	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—SUOX—polycystic ovary syndrome	0.000342	0.00073	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—AKR1C1—polycystic ovary syndrome	0.000338	0.000721	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—YAP1—polycystic ovary syndrome	0.000331	0.000707	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—GAB1—polycystic ovary syndrome	0.000327	0.000697	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ISYNA1—polycystic ovary syndrome	0.000318	0.000679	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—INSR—polycystic ovary syndrome	0.000312	0.000666	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—SULT2A1—polycystic ovary syndrome	0.000311	0.000663	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—AKR1C3—polycystic ovary syndrome	0.000297	0.000633	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—TNRC6B—polycystic ovary syndrome	0.000292	0.000623	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—YAP1—polycystic ovary syndrome	0.00029	0.000619	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PGR—polycystic ovary syndrome	0.000289	0.000617	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—polycystic ovary syndrome	0.00028	0.000598	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—CYP11A1—polycystic ovary syndrome	0.000275	0.000588	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—TEAD2—polycystic ovary syndrome	0.00027	0.000577	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—AKR1C2—polycystic ovary syndrome	0.00027	0.000577	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PLAT—polycystic ovary syndrome	0.000269	0.000574	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—GHRL—polycystic ovary syndrome	0.000269	0.000574	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—AKR1C3—polycystic ovary syndrome	0.00026	0.000555	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—POMC—polycystic ovary syndrome	0.000259	0.000553	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—ATF1—polycystic ovary syndrome	0.000256	0.000547	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—CYP17A1—polycystic ovary syndrome	0.000256	0.000546	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—TCF7L2—polycystic ovary syndrome	0.00025	0.000534	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—AKT2—polycystic ovary syndrome	0.000249	0.000531	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—BCL2—polycystic ovary syndrome	0.000245	0.000522	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—NGFR—polycystic ovary syndrome	0.000237	0.000505	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—IL6—polycystic ovary syndrome	0.000235	0.000503	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—POMC—polycystic ovary syndrome	0.000235	0.000502	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PRL—polycystic ovary syndrome	0.000235	0.000501	CbGpPWpGaD
Tafluprost—PTGS2—Disease—RPL37A—polycystic ovary syndrome	0.00023	0.000491	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PNPLA2—polycystic ovary syndrome	0.000227	0.000484	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—AKT2—polycystic ovary syndrome	0.000226	0.000482	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—ADRB2—polycystic ovary syndrome	0.000222	0.000475	CbGpPWpGaD
Tafluprost—PTGS2—Disease—HMMR—polycystic ovary syndrome	0.000218	0.000465	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—SRD5A1—polycystic ovary syndrome	0.000215	0.000458	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—GNAS—polycystic ovary syndrome	0.000206	0.00044	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—STAR—polycystic ovary syndrome	0.000205	0.000437	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	0.000203	0.000432	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—NCOR1—polycystic ovary syndrome	0.000197	0.000419	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—NRG1—polycystic ovary syndrome	0.000193	0.000412	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—IL6—polycystic ovary syndrome	0.000186	0.000397	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—polycystic ovary syndrome	0.000183	0.000391	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—HMMR—polycystic ovary syndrome	0.000183	0.00039	CbGpPWpGaD
Tafluprost—PTGS2—Disease—AKR1C1—polycystic ovary syndrome	0.00018	0.000383	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—HSD3B1—polycystic ovary syndrome	0.000174	0.000372	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	0.000172	0.000368	CbGpPWpGaD
Tafluprost—PTGS2—Disease—FGF18—polycystic ovary syndrome	0.000167	0.000356	CbGpPWpGaD
Tafluprost—PTGS2—Disease—RBP4—polycystic ovary syndrome	0.000165	0.000353	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—IRS2—polycystic ovary syndrome	0.000165	0.000353	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	0.000163	0.000348	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—LEP—polycystic ovary syndrome	0.000162	0.000345	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—LHB—polycystic ovary syndrome	0.000159	0.000339	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—HSD3B2—polycystic ovary syndrome	0.000155	0.000331	CbGpPWpGaD
Tafluprost—PTGS2—Disease—GAB1—polycystic ovary syndrome	0.000152	0.000325	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—AKR1C1—polycystic ovary syndrome	0.00015	0.000321	CbGpPWpGaD
Tafluprost—PTGS2—Disease—NAMPT—polycystic ovary syndrome	0.000148	0.000316	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—IRS1—polycystic ovary syndrome	0.000144	0.000308	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—POMC—polycystic ovary syndrome	0.000139	0.000296	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—SULT2A1—polycystic ovary syndrome	0.000138	0.000295	CbGpPWpGaD
Tafluprost—PTGS2—Disease—AKR1C3—polycystic ovary syndrome	0.000138	0.000295	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—INS—polycystic ovary syndrome	0.000138	0.000295	CbGpPWpGaD
Tafluprost—PTGS2—Disease—TNRC6B—polycystic ovary syndrome	0.000136	0.00029	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—RRM2—polycystic ovary syndrome	0.000134	0.000286	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—IGF1—polycystic ovary syndrome	0.000134	0.000285	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—AKT2—polycystic ovary syndrome	0.000134	0.000285	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—YAP1—polycystic ovary syndrome	0.000129	0.000276	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—SERPINE1—polycystic ovary syndrome	0.000127	0.000271	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—NAMPT—polycystic ovary syndrome	0.000124	0.000265	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	0.000123	0.000263	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CYP11A1—polycystic ovary syndrome	0.000123	0.000262	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	0.000122	0.00026	CbGpPWpGaD
Tafluprost—PTGS2—Disease—TCF7L2—polycystic ovary syndrome	0.000117	0.000249	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—AKR1C3—polycystic ovary syndrome	0.000116	0.000247	CbGpPWpGaD
Tafluprost—PTGS2—Disease—SLC2A4—polycystic ovary syndrome	0.000115	0.000245	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CYP17A1—polycystic ovary syndrome	0.000114	0.000243	CbGpPWpGaD
Tafluprost—PTGS2—Disease—PRL—polycystic ovary syndrome	0.000109	0.000233	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—IL6—polycystic ovary syndrome	0.000102	0.000218	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—TH—polycystic ovary syndrome	9.86e-05	0.000211	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—SLC2A4—polycystic ovary syndrome	9.59e-05	0.000205	CbGpPWpGaD
Tafluprost—PTGS2—Disease—NCOR1—polycystic ovary syndrome	9.16e-05	0.000195	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CYP19A1—polycystic ovary syndrome	9.02e-05	0.000193	CbGpPWpGaD
Tafluprost—PTGS2—Disease—NRG1—polycystic ovary syndrome	8.99e-05	0.000192	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—VEGFA—polycystic ovary syndrome	8.73e-05	0.000186	CbGpPWpGaD
Tafluprost—PTGS2—Disease—MTHFR—polycystic ovary syndrome	8.09e-05	0.000173	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—GNAS—polycystic ovary syndrome	8.05e-05	0.000172	CbGpPWpGaD
Tafluprost—PTGS2—Disease—IRS2—polycystic ovary syndrome	7.7e-05	0.000164	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—NCOR1—polycystic ovary syndrome	7.67e-05	0.000164	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CYP1A1—polycystic ovary syndrome	7.27e-05	0.000155	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—MTHFR—polycystic ovary syndrome	6.78e-05	0.000145	CbGpPWpGaD
Tafluprost—PTGS2—Disease—IRS1—polycystic ovary syndrome	6.72e-05	0.000143	CbGpPWpGaD
Tafluprost—PTGS2—Disease—INS—polycystic ovary syndrome	6.44e-05	0.000137	CbGpPWpGaD
Tafluprost—PTGS2—Disease—AKT2—polycystic ovary syndrome	6.22e-05	0.000133	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—IL6—polycystic ovary syndrome	6.04e-05	0.000129	CbGpPWpGaD
Tafluprost—PTGS2—Disease—SERPINE1—polycystic ovary syndrome	5.91e-05	0.000126	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PPARG—polycystic ovary syndrome	5.5e-05	0.000117	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—POMC—polycystic ovary syndrome	5.42e-05	0.000116	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—INS—polycystic ovary syndrome	5.39e-05	0.000115	CbGpPWpGaD
Tafluprost—PTGS2—Disease—IL6—polycystic ovary syndrome	2.81e-05	6e-05	CbGpPWpGaD
